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Human DEC (differentially expressed in chondro-
cytes), mouse STRA (stimulated with retinoic acid), and
rat SHARP (split and hairy related protein) proteins
constitute a new and structurally distinct class of the
basic helix-loop-helix proteins. In each species, two
members are identified with a sequence identity of
>90% in the basic helix-loop-helix region and 40% in
the total proteins, respectively. Recently, we have re-
ported that DEC1 is abundantly expressed in colon car-
cinomas but not in the adjacent normal tissues. The
present study was undertaken to extend the expression
study of DEC1 and to determine whether DEC1 and
DEC2 had similar expression patterns among paired
cancer-normal tissues from the colon, lung, and kidney.
Without exceptions, DEC1 was markedly higher in the
carcinomas, whereas the opposite was true with DEC2.
In stable transfectants, tetracycline-induced expression
of DEC1 caused proportional decreases in the expres-
sion of DEC2. Co-transfection with DEC1 repressed the
activity of a DEC2 promoter reporter by as much as 90%.
The repression was observed with wild type DEC1 but
not its DNA binding-defective mutants. Studies with de-
letion and site-directed mutants located, in the proximal
promoter, an E-box motif that supported the DEC1-me-
diated repression. Disruption of this E-box markedly
abolished the ability of the reporter to respond to DEC1.
Our findings assign for DEC1 the first target gene that is
regulated through direct DNA binding. DEC/STRA/
SHARP proteins are highly identical in the DNA binding
domain but much more diverse in other areas. DEC1-
mediated repression on the expression of DEC2 pro-
vides an important mechanism that these transcription
factors regulate the cellular function not only by modu-
lating the expression of their target genes but also the
expression of members within the same class.
The basic helix-loop-helix (bHLH)1 proteins are intimately
associated with developmental events such as cell differentia-
tion and lineage commitment (1–6). The HLH domain in the
bHLH motif is responsible for dimerization, whereas the basic
region mediates DNA binding (1). Based on sequence align-
ment and domain analysis, human DEC (differentially ex-
pressed in chondrocytes), mouse STRA (stimulated with reti-
noic acid), and rat SHARP (split and hairy related protein)
constitute a new and structurally distinct class of bHLH pro-
teins (7–10). These proteins are distantly related to Drosophila
Hairy and E(spl) as well as the mammalian homologues (e.g.
HES) with the highest sequence identity (40%) in the bHLH
region (1, 11, 12). Like Hairy/E(spl)/Hes, DEC/STRA/SHARPs
contain an orange domain and a proline residue in the DNA
binding domain. However, the proline is located 2 residues
more toward the NH2 terminus (1, 8). Another major structural
difference on the functional domains is that DEC/STRA/
SHARPs, unlike Hairy/E(Spl)/Hes proteins, lack the COOH-
terminal WRPW tetrapeptide motif (13). Through this se-
quence, Hairy/E(spl)/Hes recruit corepressor Groucho to the
transcription regulatory complex (13). Recruitment of Groucho
is responsible for a vast array of biological activities of Hairy/
E(spl)/Hes proteins including cellular differentiation and line-
age commitment (14–18).
Two members of DEC/STRA/SHARP proteins are identified
in each mammalian species studied with a sequence identity of
90% in the bHLH region and 40% in the total proteins,
respectively (8). They exhibit an overlapping tissue distribu-
tion, and their expression is highly elevated in response to
environmental stimuli (7–10). In rats that undergo seizure
induction by kainic acid, the levels of mRNA encoding SHARP1
or -2 are sharply increased within 1 h in the brain (9). In
cultured human cells, both DEC1 and DEC2 are markedly
induced in response to hypoxia (19). Co-transfection experi-
ments with promoter reporters have identified functional hy-
poxia response elements in both DEC1 and DEC2 genes. These
elements show high affinity toward hypoxia-inducible factor-1
and -, providing a molecular explanation on the co-regulatory
phenomena of DEC1 and DEC2 during hypoxia response (19).
Rapid induction of these proteins in response to environmental
stimuli suggests that DEC/STRA/SHARPs are protective
against detrimental conditions.
In addition to a potential protective role against environmen-
tal stimuli, DEC/STRA/SHARPs have been implicated in cell
differentiation (7, 10, 20), maturation of lymphocytes (21), and
regulation of molecular clock (22). In a cell culture system,
mouse STRA13 promotes neuronal but represses mesodermal
and endodermal differentiation (7). Consistent with the induc-
tive effect on neuronal differentiation, rat SHARP proteins are
abundantly expressed in a subset of mature neurons (9). DEC1
has recently been shown to promote chondrocyte differentia-
tion at the early and terminal stages (20). STRA13-deficient
mice, although surviving to adulthood, develop autoimmune
diseases accompanied by accumulation of spontaneously acti-
vated T and B cells (21). In addition, the mouse proteins are
recently found to regulate the expression of biological clock
regulator Per (22). Recently, we and other investigators have
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recently demonstrated that deregulated cell survival by DEC1
may have oncogenic significance. In paired samples, DEC1 is
abundantly expressed in colon carcinomas but not in the adja-
cent normal tissues (23). High levels of DEC1 transcript are
also detected in an array of cancer cell lines derived from a wide
range of organs (24). Cells that lack the functional tumor sup-
pressor VHL (von Hippel-Lindau) express higher levels of
DEC1 (24). Forced expression of DEC1 antagonizes serum dep-
rivation-induced apoptosis and selectively inhibits the activa-
tion of procaspases (23). These findings suggest that overex-
pression of DEC1 provides cells with an unusual survival
mechanism and thus is oncogenic.
The present study was undertaken to extend the expression
study on DEC1 and to determine whether DEC1 and DEC2
displayed similar expression patterns among paired tumor-
normal tissues from the colon, lung, and kidney. Without ex-
ceptions, DEC1 was expressed markedly higher in the carcino-
mas, whereas DEC2 was expressed markedly higher in the
adjacent normal tissues. Forced expression of DEC1 sharply
decreased the expression of DEC2 and markedly repressed the
activity of a DEC2 promoter reporter. Co-transfection experi-
ments with mutant reporters and electrophoretic mobility shift
assay (EMSA) located, in the proximal promoter, an E-box that
supports DEC1-mediated repression. These findings provide
direct evidence that DEC1 negatively regulates the expression
of DEC2, which is largely achieved through direct DNA binding
to the E-box in the proximal promoter of DEC2.
MATERIALS AND METHODS
Chemicals and Supplies—Tri-reagent, FLAG-cytomegalovirus vec-
tor, and anti-FLAG antibody were purchased from Sigma. The goat
anti-rabbit-IgG conjugated with alkaline phosphatase or horseradish
peroxidase and ECL substrate were from Pierce. Dulbecco’s modified
Eagle’s medium, LipofectAMINE, and the ThermoScript I reverse tran-
scription-coupled PCR kit were from Invitrogen. The Dual-Luciferase
reporter assay system and DNA binding buffer were from Promega.
Unless otherwise indicated, all other reagents were purchased from
Fisher.
Tissue Collection and Processing—Samples were collected from pa-
tients who underwent surgical resection for histologically confirmed
adenocarcinoma. As paired controls, specimens from the adjacent,
grossly normal tissues were harvested. The samples (12 pairs) were
collected from the colon, kidney, and lung with four pairs from each
organ. The age of the patients was between 23 and 68 with seven male
and five female. The size of tumors was generally 2–5 cm in diameter,
and the degree of differentiation of tumors was moderate or poor as
determined by pathological examination. Samples were freshly proc-
essed for RNA isolation and protein extraction. Total RNA was isolated
with a Tri-reagent as described previously (25). For the preparation of
protein extracts, tissues were homogenized in lysis buffer (20 mM Tris-
HCl, pH 7.4, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 0.2
mM phenylmethylsulfonyl fluoride, and 1 mM dithiothreitol). The ho-
mogenates were centrifuged at 12,000  g for 30 min to remove any
insoluble precipitates. The protocol of using human pathological tissues
was reviewed by the Institutional Review Board.
RT-PCR—The expression of DEC1 and DEC2 in human tissues and
cultured cells was primarily determined by RT-PCR experiments with
a ThermoScript I kit. Total RNA (2 g) was subjected to the synthesis
of the first strand cDNA with an oligo(dT) primer and a ThermoScript
reverse transcriptase. The reactions were incubated initially at 50 °C
for 30 min and then at 60 °C for 60 min after additional reverse
transcriptase was added. The cDNAs were then subjected to PCR am-
plification with cycling parameters as follows: 95 °C for 30 s, 52 °C for
30 s, and 68 °C for 30 or 40 s for a total of 32 cycles. The primers for
DEC1 amplification were 5-GTCTGTGAGTCACTCTTCAG-3 and 5-
GAGTCTAGTTCTGTTTGAAGG-3. The primers for DEC2 amplifica-
tion were 5-CGCCCATTCAGTCCGACTTGGAT-3 and 5-TGGTT-
GATCAGCTGGACACAC-3. The primers for -actin amplification were
5-GTACCCTGGCATTGCCGACAGGATG-3 and 5-CGCAACTAAGT-
CATAGTCCGCCTA-3. The PCR-amplified products were analyzed by
agarose gel electrophoresis.
Plasmid—A cDNA encoding the full-length DEC1 was isolated by a
cDNA-trapping method (23, 26). Several DEC1 mutant constructs were
prepared by PCR with the full-length DEC1 as the template. These
mutants had a specific sequence deleted or one or more amino acids
substituted. Some of the mutant constructs were prepared with the
SPORT vector (the NH2-terminal truncated mutants), whereas others
(the COOH-terminal truncated mutants) were prepared with the FLAG
vector to facilitate immunodetection. In some cases, a Kozak sequence
was introduced for effective translation initiation. The DEC2 promoter
reporter was prepared with the pGL3-basic luciferase vector (Promega).
Human genomic DNA was isolated from the placenta with a DNA
extraction kit (Qiagen) according to the manufacturer’s instruction. A
genomic fragment (1,888 to 11) was generated by PCR with 5-
AACAGATGAACTGAACGGACCG-3 and 5-CCTCAGTGCAGTGTT-
GAAAGTG-3. This PCR fragment was ligated to the pGL3 vector.
Deletion mutants of this reporter were prepared by endonuclease di-
gestion followed by ligation or PCR.
Site-directed Mutagenesis—The DEC2 promoter reporter had two
E-box motifs that probably interact with DEC1, and the studies with
deletion mutants suggested that the E-box in the proximal region
supports DEC1-mediated repression. In order to definitively establish
such a role, site-directed mutagenesis was performed to substitute two
of the six nucleotides. The mutant construct was prepared with a
QuikChange site-directed mutagenesis kit (Stratagene). Complemen-
tary oligonucleotides (5-GATGGTACGTTCCGAACGGGAGCTGGGT-
GCTGG-3) were synthesized to target this region. To perform the
substitutions, the primers were annealed to a DEC2 promoter reporter
and subjected to a thermocycler for a total of 15 cycles. The resultant
PCR-amplified constructs were then digested with DpnI to remove the
nonmutated parent construct. The mutated PCR-amplified constructs
were used to transform XL1-Blue. The same approach was used to
prepare three DEC1 mutants that had single or double residues sub-
stituted in the DNA binding domain (P56A, R58P, or both). The general
sequence for the site-directed mutagenic oligonucleotides was 5-
GAGACCTACAAATTGGCGCACCCGCTCATCGAGAAAAAGAG-3
with the nucleotides in boldface type substituted individually or simul-
taneously. All mutated constructs were subjected to sequencing analy-
sis to confirm the desired mutation being made without secondary
mutations.
Co-transfection Experiment—Cells (293T) were plated in 24-well
plates in Dulbecco’s modified Eagle’s medium supplemented with 10%
fetal calf serum at a density of 1.6  105 cells/well. Transfection was
conducted by lipofection with LipofectAMINE according to the manu-
facturer’s instructions. Transfection mixtures contained DEC1 or a
mutant construct (100 ng), reporter plasmid (100 ng), and the pRL-TK
Renilla plasmid (1 ng). If a DEC1-stable line was used, DEC1 or its
mutant construct was omitted from the transfection mixture. The
transfected cells were cultured for an additional 24 h, washed once with
phosphate-buffered saline, and resuspended in passive lysis buffer (Pro-
mega). The lysed cells were subjected to two cycles of freezing/thawing.
The reporter enzyme activities were assayed with a Dual-Luciferase
reporter assay system. This system contained two substrates, which
were used to determine the activity of two luciferases sequentially. The
firefly luciferase activity, which represented the reporter gene activity,
was initiated by mixing an aliquot of lysates (20 l) with Luciferase
Assay Reagent II. Then the firefly luminescence was quenched, and the
Renilla luminescence was simultaneously activated by adding Stop &
Glo reagent to the sample wells. The firefly luminescence signal was
normalized based on the Renilla luminescence signal. In cases where
the reading on the luciferase activity was too high, the lysates were
diluted, and luciferase activities were then determined to minimize the
interference on the reading of the Renilla luciferase activity.
EMSA—Cells (293T) were transfected with DEC1 or a mutant, and
nuclear extracts were prepared with a nuclear extraction kit (Active
Motif). In some cases, DEC1-stable transfected cells were used but
cultured in the presence or absence of tetracycline to modulate the
expression of transfected DEC1. Nuclear proteins (10 g) were incu-
bated with radiolabeled double-stranded oligonucleotides (5-CGTTC-
CGCACGTGAGCTGGG-3) in a final volume of 10 l containing 1
DNA binding buffer. For competition experiments, nuclear extracts
were first incubated with a 10- or 50-fold molar excess of cold probe and
then mixed with the radiolabeled probe. Oligonucleotides with a dis-
rupted E-box were also used in the competition assays. For supershift
assays, the anti-DEC1 or an anti-FLAG antibody was added either
before or after the nuclear extracts were incubated with the radiola-
beled probe. The protein-DNA complexes were resolved in 6% PAGE
and visualized by autoradiography.
Other Analyses—Western analyses were conducted as described pre-
viously (27). The anti-DEC1 antibody against the COOH-terminal pep-
tide was described elsewhere (23). Protein concentration was deter-
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mined with BCA assay (Pierce) with bovine serum albumin as the
standard. Data are presented as mean  S.D. of at least four separate
experiments, except where results of blots are shown, in which case a
representative experiment is depicted in the figures.
RESULTS
DEC1 and DEC2 Are Inversely Expressed in Paired Carcino-
mas and Adjacent Normal Tissues—We have reported that
DEC1 is abundantly expressed in colon carcinoma but not in
the adjacent normal tissues (23). The initial focus of the pres-
ent study was to extend the expression study on DEC1 and to
determine whether DEC1 and DEC2 shared similar expression
patterns among paired cancer-normal tissues from the colon,
kidney, and lung. RT-PCR experiments with primers specific to
DEC1 and DEC2 were performed. As shown in Fig. 1, without
exceptions, the levels of DEC1 mRNA were markedly higher in
the carcinomas, whereas the levels of DEC2 mRNA were mark-
edly higher in the adjacent normal tissues. Between paired
samples, the levels of -actin mRNA were comparable. The
carcinoma-related increase in DEC1 expression was also de-
tected by Western blot (top of each depicted figure), suggesting
that mRNA levels are indicative of the overall expression of
these two genes.
Forced Expression of DEC1 Proportionally Decreases the Ex-
pression of DEC2—The inversed expression patterns between
DEC1 and DEC2 suggest that DEC1 negatively regulates the
expression of DEC2 or vice versa. In order to directly test this
possibility, DEC1-stable transfected lines were used to study
the expression relationship between DEC1 and DEC2. Two
clonal stable lines were included: one expressing DEC1 (wild
type) and the other expressing DEC1-M, which lacked the DNA
binding domain. The stable lines were prepared with 293T cells
and the pcDNA6/TR-pcDNA4 expression system; therefore, the
expression of DEC1 and DEC1-M was inducibly regulated by
tetracycline as described previously (23). As expected, the ad-
dition of tetracycline caused a concentration-dependent in-
crease on the levels of DEC1 as determined by Western blots
(Fig. 2A, top). Consistent with the inducible increase in the
levels of DEC1 protein, the levels of DEC1 mRNA were propor-
tionally increased (data not shown). In contrast to the in-
creased expression of DEC1, the levels of DEC2 mRNA were
proportionally decreased (Fig. 2A). However, such inversed
expression patterns were observed only in the cells expressing
wild-type DEC1 (Fig. 2A) and not the cells expressing the
DEC1 mutant, although the levels of DEC1-M were markedly
induced by tetracycline (Fig. 2B).
The E-box in the Proximal Promoter of DEC2 Is the Sequence
Targeted by DEC1—The inability of DEC1-M to down-regulate
the expression of DEC2 suggests that DEC1-mediated repres-
sion is achieved through a DNA-binding mechanism. In order
to directly test this possibility, reporter experiments and
EMSA were conducted. A DEC2 promoter reporter (pLuc-1888)
was constructed to contain the basal promoter and other po-
tential regulatory sequences of the DEC2 gene (1,888 to11).
This region was chosen because it contained two E-box motifs
that commonly serve as target sequences for bHLH transcrip-
tion factors (1). A series of 5 deletion mutants of this reporter
was also prepared and designed to specify the location of DNA
sequence that is targeted by DEC1 (Fig. 3A, left). Co-transfec-
tion experiments were conducted to test these reporters for
their ability to support DEC1-mediated activity. The stable
transfected line (wild-type DEC1 only) was transfected again
with a reporter construct and cultured in the presence or ab-
sence of tetracycline to modulate the expression of DEC1. The
pRL-TK Renilla plasmid was also included in the transfection
mixture to normalize transfection efficiency. As described in
Fig. 3A (right), the addition of tetracycline decreased the activ-
ity of the pLuc-1888 reporter by as much as 90%. Similar
repression was observed with the reporters that had the se-
quence deleted up to nucleotide 535. In contrast, reporter
pLuc-125, which had a further deletion from nucleotide 535
to 125, simultaneously lost the basal transcription activity
and the ability to respond to DEC1, suggesting the importance
of this region (535 to 125) in both basal and regulatory
transcription.
We next examined whether responsiveness to DEC1 could be
separated from the basal transcription activity in the DEC2
promoter reporter. Given the fact that this region (535 to
125) contains a single E-box that is probably targeted by
FIG. 1. Inversed expression patterns of DEC1 and DEC2 in the
carcinoma and the adjacent normal tissues from the colon, kid-
ney, and lung. Total RNA (5 g) of carcinoma-normal paired samples
from the colon, kidney, and lung was subjected to RT-PCR analyses
with a ThermoScript I kit. For PCR amplification, a master tube con-
taining all common reagents was prepared and equally distributed to
individual PCR tubes (DEC1, DEC2, and -actin). PCR amplification
was conducted with cycling parameters as follows: 95 °C for 30 s, 52 °C
for 30 s, and 68 °C for 30 or 40 s for a total of 32 cycles. The PCR-
amplified products were analyzed by agarose gel electrophoresis and
visualized by ethidium bromide staining. For Western blotting analysis,
homogenates (10 g) were subjected to SDS-PAGE. The immunoblot
was incubated with the antibody against DEC1. The primary antibody
was then located by horseradish peroxidase-conjugated goat anti-rabbit
IgG and visualized with chemiluminescent substrate.
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DEC1, a reporter with this E-box disrupted was tested for the
ability to confer basal transcription. Reporter pLuc-535 was
subjected to site-directed mutagenesis to selectively disrupt the
E-box (CACGTG to AACGGG). Similarly, co-transfection ex-
periments were performed. As shown in Fig. 3A (bottom), dis-
ruption of this E-box (pLuc-535-M) caused little change in the
basal activity (cultured without tetracycline), suggesting that
this E-box contributes little to basal transcription. In contrast,
the reporter mutant (pLuc-535-M) exhibited only35% repres-
sion in response to DEC1 (Fig. 3A, lane 8), which contrasts
strikingly with 90% repression observed with the correspond-
ing nonmutagenic reporter (Fig. 3A, lane 5). These findings
suggest that the proximal E-box is largely responsible for
DEC1-mediated repression. It should be emphasized that a
similar observation was made with a substitution mutant re-
porter prepared from the longest reporter pLuc-1888, and the
expression levels of DEC1 were comparable among all cells as
determined by Western blots (data not shown).
We next examined whether this E-box interacted directly
with DEC1. The DEC1-stable line was cultured in the presence
or absence of tetracycline, and nuclear extracts were prepared.
Double-stranded oligonucleotides harboring this E-box were
synthesized and radiolabeled. The labeled probe was incubated
with the nuclear extracts and analyzed by EMSA. As shown in
Fig. 3B, incubation with the extracts from the cells cultured in
the presence of tetracycline yielded a shifted band (lane 8). This
band was not detected when incubation was performed with
the extracts from the cell cultured without tetracycline (lane 7).
The shifted band was competed completely by 50 (lane 1) or
partially by 10 excess cold probe (lane 3). However, the oli-
gonucleotides (50) that harbored a mutated E-box (E-box-M)
showed no competitive activity (lane 2). In addition, the shifted
band was supershifted by the anti-DEC1 but not the anti-
FLAG antibody. The supershifted band appeared whether the
antibody was added before or after the DEC1-DNA complexes
were formed (lanes 5 and 6), suggesting that the antibody
binding does not interfere with interactions between DEC1 and
its element (the antibody directed against the COOH-terminal
sequence of DEC1).
DNA Binding Is Required to Effectively Repress the DEC2
Promoter Reporter—Disruption of the proximal E-box caused
drastic but incomplete loss of responsiveness to DEC1 (Fig. 3A),
suggesting that DNA binding is not the only mechanism in-
volved in DEC1-mediated repression on the DEC2 reporter or
that an additional DEC1 binding site exists in this region. We
next tested whether DEC1 mutants, defective of DNA binding,
had any repressive activity. These mutants had one or more
residues in the DNA binding domain substituted or one or more
structural domains deleted (Fig. 4A). A total of three deletion
mutants (DEC1-M, DEC1105–412 and DEC1237–412) were pre-
pared, and all of them lacked the DNA binding domain. As
shown in Fig. 4A, additional sequences were also deleted in
DEC1105–412 (the HLH motif) and DEC1237–412 (the HLH motif
and orange domain). The HLH motif and the orange domain
are shown in other bHLH proteins to mediate dimerization and
protein interactions, respectively (1). Similarly, three substitu-
tion mutants were prepared, including DEC1P56A, DEC1R58P,
and DEC1P56A/R58P. The rationale for preparing the substitu-
tion mutants was that proline 56 was assumed to be critical in
DNA binding based on studies with other bHLH proteins (1).
However, there is a major difference regarding the location of
this proline. In other bHLH proteins, the proline is located 2
residues more carboxyl terminal (corresponding to residue 58
in DEC1) (7, 8). Therefore, the mutants represented substitu-
tion of proline 56 with an alanine (DEC1P56A), arginine 58 with
a proline (DEC1R58P), or both (DEC1P56A/R58P).
Co-transfection experiments were conducted to test these
DEC1 mutants for their ability to repress the DEC2 reporter
(pLuc-1888). As shown in Fig. 4A (top), all deletion mutants
(DEC1-M, DEC1105–412, and DEC1237–412) exhibited little re-
pressive activity toward this reporter. In contrast, all substi-
tution mutants repressed the DEC2 reporter, but the overall
repressive activity varied markedly among them. The
DEC1P56A mutant showed a similar potency as the wild-type
DEC1 (90% repression), whereas the other two mutants
(DEC1R58P and DEC1P56A/R58P) caused only 65 and 50%
repression, respectively. The expression of DEC1 and its mu-
tants was comparable with the exception of DEC1-M that was
expressed to a higher extent (Fig. 4B), excluding the possibility
that lack of expression was a contributing factor to the weaker
repression by some of the mutants (e.g. DEC1P56A/R58P). In
order to determine whether these mutants, particularly the
mutants DEC1R58P and DEC1P56A/R58P, indeed lost DNA bind-
ing ability, nuclear extracts from the respective transfected
cells were incubated with the radiolabeled E-box oligonucleo-
tides, and the corresponding DNA-protein complexes were an-
alyzed by EMSA. As predicted, all deletion mutants (DEC1-M,
FIG. 2. Repressed expression of DEC2 by DEC1 in stable trans-
fected cells. Stable transfected cells by DEC1 (A) or DEC1-M (B) were
seeded in six-well plate. After reaching 80% confluence, cells were
treated with tetracycline at various concentrations (0–1 g/ml) for 24 h.
Total RNA and homogenates were prepared and analyzed for the ex-
pression of DEC1 by Western blots or DEC2 by RT-PCR as described in
the legend for Fig. 1. Similarly, the expression of -actin was deter-
mined and served as control.
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DEC1105–412, and DEC1237–412) showed no DNA binding activ-
ity (result shown for DEC1-M only) (Fig. 4C). In contrast, DNA
binding activity varied among the substitution mutants.
DEC1P56A showed a similar binding ability as DEC1, whereas
DEC1R58P and DEC1P56A/R58P had no DNA binding activity,
consistent with the fact that DEC1P56A was the only substitu-
tion mutant that effectively repressed the promoter activity of
DEC2 (Fig. 4A).
DNA Binding Is Not Sufficient to Confer Repressive Activi-
ty—The studies with DNA binding defective mutants clearly
demonstrated the importance of DNA binding in repressing the
DEC2 promoter. We next examined whether DNA binding was
sufficient to exert repression. In order to directly test this
possibility, DEC1 mutants were prepared to keep the bHLH
motif intact (DNA binding) but have sequences with various
lengths deleted from the COOH terminus (Fig. 5A). These
COOH-terminal truncated mutants were subcloned in the
FLAG vector to facilitate immunodetection. Similarly, co-trans-
fection experiments were performed with DEC1 or a mutant
along with the DEC2 reporter (pLuc-1888). As shown in Fig.
5A, deletion of the COOH-terminal 65 residues (FLAG-
DEC11–347) caused no changes in the repressive activity (1). In
contrast, deletions of additional COOH-terminal sequence
caused a partial or a complete loss of repressive ability. As a
matter of fact, FLAG-DEC11–150 no longer had any repressive
activity. Western analyses were performed to confirm that the
mutants were actually expressed slightly higher than the wild
type DEC1 (Fig. 5B).
Next, we examined whether these mutants actually retained
DNA binding activity. EMSA was performed with the nuclear
extracts from the cells used for reporter assays. As shown in
Fig. 5C, a shifted band was detected with all COOH-terminal
FIG. 3. DEC1-mediated repression on the DEC2 promoter reporter and binding to the proximal E-box. A, DEC1-mediated repression
on the DEC2 promoter reporter. Deletion and site-directed mutants of the DEC2-promoter reporter (pLuc-1888) were prepared by endonuclease
digestion followed by ligation or by PCR with a QuikChange site-directed mutagenesis kit. DEC1-stable transfected cells were cultured in 24-well
plates at 80% confluence and transfected again with a reporter construct (100 ng) and the pRL-TK Renilla (1 ng). The retransfected cells were
cultured in the presence or absence of tetracycline (1 g/ml) for 24 h. The cells were collected, washed once with phosphate-buffered saline, and
resuspended in passive lysis buffer. The reporter enzyme activities were assayed with a Dual-Luciferase reporter assay system. The firefly
luminescence signal was normalized based on the Renilla luminescence signal. B, EMSA DEC1-stable transfected cells were cultured in the
presence or absence of tetracycline (tet; 1 g/ml) for 24 h, and nuclear extracts were prepared with a nuclear extraction kit (Active Motif). Nuclear
proteins (10 g) were incubated with radiolabeled double-stranded oligonucleotides harboring the proximal E-box in a final volume of 10 l
containing 1DNA binding buffer. For competition experiments, nuclear extracts were first incubated with excess cold probe (50 in lane 1 or 10
in lane 3) and then mixed with the radiolabeled probe. Oligonucleotides (M) with the E-box disrupted were also used in the competition assays (50
in lane 2). For supershift assays, the anti-DEC1 antibody (D) was added either before (lane 5) or after (lane 6) the nuclear extracts were incubated
with the radiolabeled probe. As a control, the anti-DEC1 antibody was replaced by an anti-FLAG antibody (F, lane 4). The protein-DNA complexes
were resolved in 6% polyacrylamide gel electrophoresis and visualized by autoradiography.
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truncated mutants. The relative electrophoretic mobility was
generally associated with the size of a mutant. For example,
FLAG-DEC11–150 was the shortest among the mutants, and the
shifted band with this mutant exhibited the fastest mobility.
More importantly, the addition of an anti-FLAG antibody into
the binding reactions resulted in the appearance of a super-
shifted band accompanied by the disappearance of the original
shifted band, providing direct evidence that the observed pro-
tein-DNA interactions were highly specific. These findings also
suggest that DNA binding, although essential, is not sufficient
to confer repressive effect.
The HLH Motif Is Required for Dominant Interfering Regu-
lation—The inability of FLAG-DEC11–150 to exert repression,
although it bound effectively to DNA, points to two important
possibilities: the deleted region from residue 150 to 347 has
intrinsic repressive activity, or this region is responsible for
recruiting protein(s) that causes repression. Apparently, com-
prehensive experiments are required to definitively establish
the involvement of each possibility. However, we examined the
second possibility by testing mutants that contained part or the
entire sequence of this region for the ability to function as a
dominant interfering regulator. Co-transfection experiments
were conducted with DEC1 in the presence and absence
of a mutant. Among mutants DEC1-M, DEC1105–412, and
DEC1237– 412, only DEC1-M effectively reversed DEC1-
mediated repression (Fig. 6A), although they all shared two
important features; they lacked the entire DNA binding do-
main and lacked repressive activity themselves (Fig. 4A).
Among the substitution mutants, DEC1
R58P
and DEC1P56A/R58P
but not DEC1P58A partially but significantly reversed DEC1-
mediated repression, consistent with the fact that DEC1P58A
was a potent repressor itself (as potent as wild type DEC1),
whereas DEC1R58P and DEC1P56A/R58P were much less repres-
sive (Fig. 4A). It should be emphasized that the expression
patterns in the cells co-transfected with DEC1 and a mutant
were consistent with what was predicted; a band with more
intensified staining was detected if a mutant co-migrated with
DEC1 (e.g. DEC1P56A/R58P); otherwise, an additional band (e.g.
DEC1105–412) was detected if a mutant and DEC1 were elec-
trophoretically distinct.
We also tested all COOH-terminal truncated mutants for the
ability to function as dominant interfering regulators. Gener-
ally, these mutants either partially or completely antagonized
DEC1-mediated repression, depending on the relative potency
to act as a repressor by its own (Fig. 6B). Mutants with less
intrinsic repressive activity exhibited a higher potency to re-
verse the repression by DEC1. For example, FLAG-DEC11–150
itself had no repressive activity (Fig. 4A) but completely re-
versed DEC1-mediated repression (Fig. 6B). Among all mu-
tants that were less repressive than wild type DEC1, only
DEC1105–412 and DEC1237–412 failed to reverse the repression
by DEC1 (Fig. 6), and they were the only mutants that did not
contain the HLH domain (Figs. 4A and 5A), suggesting that the
dominant interfering regulatory activity is achieved through
the HLH domain. The HLH domain is known to mediate dimer-
ization (1), and mutants with an intact HLH domain probably
FIG. 4. Essentiality of DNA binding
for DEC1 to repress DEC2 promoter
activity. A, co-transfection experiment.
Cells (293T) were cultured in 24-well
plates and transiently transfected with
DEC1 or a DNA binding defective mutant
(100 ng), DEC2 promoter reporter (pLuc-
1888; 100 ng) and the pRL-TK Renilla (1
ng). After a 24-h incubation, cells were
collected and analyzed for luciferase ac-
tivities. Similarly, firefly luminescence
signal was normalized based on the Re-
nilla luminescence signal, and the ratios
from the cells transfected with the vector
were calculated as 100%. B, immunoblot-
ting analysis. The cell lysates (10 g)
from the cells used for reporter activity
were analyzed for the expression of DEC1
or its mutants by anti-DEC1 antibody as
described in the legend to Fig. 1. C,
EMSA. Nuclear contracts were prepared
from cells transiently transfected with
DEC1 or a mutant and incubated with the
radiolabeled proximal E-box probe. The
DNA-protein complexes were resolved by
PAGE.
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form dimers with wild type DEC1, but the resultant dimers
have no DNA binding activity or are transcriptionally inactive.
In support of the first possibility, we performed EMSA and
found that DEC1R58P and DEC1P56A/R58P (DNA binding-defec-
tive mutants) markedly abolished the DNA binding ability of
DEC1 when cells were co-transfected together with DEC1 and
DEC1R58P or DEC1P56A/R58P (data not shown).
DISCUSSION
The bHLH proteins are intimately associated with develop-
mental events such as cell differentiation and lineage commit-
ment (1). Based on sequence alignment and functional domain
analyses, human DEC proteins, along with mouse STRA and
rat SHARP, constitute a new class of bHLH transcription fac-
tors (7–10). These proteins are shown to play important roles in
cell differentiation, regulation of molecular clock, immune re-
sponse, and xenobiotic response (7, 10, 19–22, 28). Recently, we
have reported that DEC1 is abundantly expressed in colon
carcinomas, antagonizes serum deprivation-induced apoptosis,
and selectively inhibits the activation of procaspases (23). In this
report, we describe inversed expression patterns between DEC1
and DEC2 among paired tumor-normal samples from the colon,
lung, and kidney. Experimentally forced induction of DEC1
causes proportional decreases in the expression of DEC2. Given
the fact that DEC/STRA/SHARP proteins are highly identical
(90%) in the DNA binding region, but very diverse in other
areas (40%), our findings described in this report provide an
important mechanism by which the cellular function of target
genes probably shared by these proteins can be coordinately
affected by members within the same class.
DNA binding is probably the primary mechanism responsi-
ble for DEC1-mediated repression on the expression of DEC2,
although members of DEC/STRA/SHARP protein family have
been shown to use non-DNA binding mechanism(s) (29–31).
Several lines of evidence presented in this study support this
notion. First, studies with deletion and site-directed reporter
mutants identify the proximal E-box that supports the repres-
sion by DEC1. This E-box exhibits a high affinity toward DEC1,
and disruption of this E-box markedly reduces its responsive-
ness to DEC1 (Fig. 3), suggesting that DNA binding is involved
in the DEC1-mediated repression. Second, DEC1 deletion mu-
tants (DEC1-M, DEC1105–412, and DEC1237–412), which lack
the entire DNA binding domain, show neither DNA binding
ability nor repressive activity (Fig. 4A), providing direct evi-
dence that DNA binding is required for DEC1 to repress the
DEC2 promoter. Finally, among the substitution mutants,
DEC1P58A binds to the E-box as much as wild type DEC1 and
is equally active in repression, whereas DEC1R58P and
DEC1P56A/R58P show no DNA binding ability and are much less
repressive (Fig. 4A), further supporting the notion that DEC1-
mediated repression is largely achieved through DNA binding.
It remains to be determined whether DEC1R58P and
DEC1P56A/R58P, although lacking DNA binding ability, cause
some repression. It is likely that these two mutants retain some
DNA binding ability within the cells, but the conditions em-
ployed for EMSA fail to support such interactions. Alterna-
tively, they exert repression through non-DNA binding mech-
anisms (29–31).
DNA binding, although required to exert effective repres-
FIG. 5. DNA binding is not suffi-
cient for DEC1 to repress DEC2 pro-
moter activity. A, co-transfection exper-
iment. Cells (293T) were cultured in 24-
well plates and transiently transfected
with DEC1 or a COOH-terminal trun-
cated mutant (100 ng), DEC2 promoter
reporter (pLuc-1888; 100 ng), and the
pRL-TK Renilla (1 ng). Determination
and calculation of the luciferase activities
were described in the legend to Fig. 4. B,
immunoblotting analysis. The cell lysates
(10 g) from the cells used for reporter
activity were analyzed for the expression
of DEC1 or its mutants by an anti-FLAG
antibody as described in the legend to Fig.
1. C, EMSA. Nuclear contracts were pre-
pared from cells transiently transfected
with DEC1 or a mutant and incubated
with radiolabeled oligonucleotides har-
boring the proximal E-box. Similarly,
competition experiments were performed
with excess cold probe (E) or a mutant
probe (M) as described in the legend to
Fig. 3B. For supershift assays, an anti-
FLAG (F) or the anti-DEC1 (D) was added
to the incubation mixtures before being
analyzed by PAGE.
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sion, is not sufficient to repress the DEC2 promoter. Mutant
FLAG-DEC11–150, for example, binds effectively to DNA but
shows no repressive activity (Fig. 5A). As a matter of fact,
mutants, with a deletion in the region from residue 150 to 347,
all bind to DNA as effectively as wild type DEC1 but are
markedly less repressive (Fig. 5A). In this region, several hel-
ical structures and particularly an orange domain are located
(7, 8). These structures are assumed to mediate protein-protein
interactions based on studies with other bHLH proteins (1, 7,
8). It is likely that this region recruits proteins that cause
repression. However, the necessity of protein recruitment
to repress DEC2 is unlikely, because mutants such as
DEC1105–412 contain the entire sequence of this region but
show no dominant interfering activity against wild type DEC1
(Fig. 6A), suggesting that this region has intrinsic repressive
activity. Alternatively, proteins assumed to be recruited are
abundantly expressed in the cells employed in this study. Al-
though we have not provided sufficient data to support protein
recruitment in repressing DEC2, it cannot be excluded that
such events are involved in the regulation of other genes by
DEC1, particularly given the fact mouse STRA13, a highly
identical protein to DEC1, has been shown to interact directly
with TFIIB through this region (29).
DEC/STRA/SHARPs differ significantly from other bHLH
proteins in terms of binding to DNA. Most bHLH proteins bind
to E-box (CANNTG) or N-box (CANNAG). Binding preference
is specified by the sequence in the basic region. Generally,
proline-containing basic regions have higher affinity toward
the N-box (1, 32), whereas the basic regions without a proline
preferentially recognize the E-box. DEC/STRA/SHARPs con-
tain a proline; however, this proline (residue 56 based on
DEC1) is located 2 residues more amino-terminal (8). Instead,
DEC/STRA/SHARPs have an arginine (residue 58) that substi-
tutes for the conserved proline among N-box binding bHLH
proteins. Although initial studies suggest that STRA13 has no
binding activity toward classic E- or N-box (7), PCR-based site
selection experiments have recently identified a class B type
E-box (CACGTG) that is effectively bound by DEC1 and
STRA13 (28, 33). In this study, we have demonstrated that the
contribution of Pro56 to DNA binding is insignificant because
mutant DEC1P58A is equally effective as wild type DEC1 in
DNA binding (Fig. 4C). In contrast, introduction of a proline by
substituting Arg58 completely eliminates DNA binding activity
(Fig. 4C), suggesting that residue in this location is indeed
important for E-box binding. It would be interesting to test
whether DEC1R58P and DEC1P56A/R58P show an increase in
binding to an N-box sequence. In addition, the DEC2 reporter
contains two identical E-box sequences (proximal and distal)
(Fig. 3A); however, only the proximal E-box is required for
responding to the repression by DEC1. The precise mechanism
for such a difference remains to be determined. It is likely that
the genomic context rather than an E-box alone determines
FIG. 6. Dominant interfering regulation on DEC1-mediated repression. A, effects of DNA binding-defective mutants on the repressive
activity by DEC1. Cells (293T) were cultured in 24-well plates and transiently transfected with DEC1 (50 ng) in the presence or absence of a DNA
binding-defective mutant (100 ng). Vector construct was used to equalize the amount of plasmid in each transfection. Similarly, the pRL-TK Renilla
plasmid (1 ng) was included in the transfection mixture to normalize transfection efficiency. Determination and calculation of the luciferase
activities were described in the legend to Fig. 4. To determine the expression levels of transfected constructs, cell lysates (10 g) from the cells used
for reporter activity were analyzed for the expression of DEC1 and its mutants by the anti-DEC1 antibody (specific to the COOH terminus of
DEC1). B, effects of the COOH-terminal truncated mutants on the repressive activity by DEC1. The co-transfection and immunodetection were
performed as described in the legend to Fig. 6A. However, both anti-DEC1 and anti-FLAG antibodies were simultaneously used for the
immunodetection, because the COOH-terminal truncated constructs were prepared with the FLAG-cytomegalovirus vector.
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intracellular DNA binding. In support of this possibility,
STRA13 has been shown to preferably bind to an E-box flanked
with certain nucleotides.
DEC1 and DEC2 share the DNA binding domain with an
exception of a single residue (aspartate versus glutamate, the
farthest NH2-terminal residue of this domain) (8); therefore,
DEC2 probably acts as an autoregulator. This possibility is
further supported by their highly identical sequences flanking
the DNA binding domain. Immediately COOH-terminal to the
DNA binding domain is the helix-loop-helix domain that is
identical between DEC1 and DEC2, and NH2-terminal to this
domain is an acidic residue-rich stretch in both proteins (8).
The DNA binding domain and its highly identical flanking
sequences suggest that DEC1 and DEC2 have overlapping
target genes, particularly those that are regulated through
direct DNA binding. In support of this notion, mouse proteins
(STRA13 and DEC2) have been recently shown to repress
Clock/Bmal1-induced activation of the Per promoter (22), a
gene that is involved in the regulation of the molecular clock.
Therefore, it is likely that DEC/STRA/SHARP proteins are
functionally redundant on some target genes, and such a re-
dundant mechanism provides a possible explanation that
STRA13 knockout mice develop to adulthood and show no
discernible phenotypic differences compared with their wild-
type littermates (21). It should be emphasized, however, that
DEC1 and DEC2 may not necessarily exert the same biological
activity on all target genes and in all cell types, particularly
given the fact that they have a minimal sequence identity
(40%) in the COOH-terminal half and exhibit several major
structural differences (8). Both DEC1 and DEC2 have an or-
ange domain (two helical structures spanned by 50 residues);
however, the overall sequence identity in this domain is only
moderate (50%). In addition, an alanine/glycine-rich region is
present in DEC2 but absent in DEC1. Previous studies with
STRA13 as well as the findings described in this study have
demonstrated that the region harboring the orange domain is
required to exert effective repression by both proteins (Fig. 5A)
(7). Amino acid repeats, on the other hand, are implicated in
protein folding, protein-protein interactions, and degradation
(34).
DEC1-mediated repression is probably responsible for the
differences on cell and tissue distributions between DEC1 and
DEC2. Although Northern analyses have shown that DEC1
and DEC2 have an overlapping tissue distribution (8, 10), it
remains to be determined whether they are actually expressed
in the same cell type and to a similar extent (8, 10). Some
organs with high levels of DEC1 (e.g. liver) express lower levels
of DEC2 (10). Very recently, DEC1 and DEC2 were found to
regulate the mammalian molecular clock, but they exhibit dis-
tinct and area-dependent expression patterns in the brain (21).
In this report, we have demonstrated that these two proteins
exhibit inversed expression patterns among the paired tumor-
normal tissues, and forced expression of DEC1 causes propor-
tional decreases in the expression of DEC2 (Figs. 1 and 2),
providing direct evidence that increased expression of DEC1 is
at least in part responsible for decreased expression of DEC2 in
a given cell context. DEC1-mediated repression, although pro-
found, may not always dictate the expression of DEC2. For
example, DEC1 and DEC2 are both up-regulated in response to
hypoxia induction (19). Acute hypoxia is considered severe
cytotoxic stimulus, and rapid induction of both genes maxi-
mizes the cellular survival mechanism based on our recent
report that DEC1 is antiapoptotic (23), although it remains to
be determined whether DEC2 is actually antiapoptotic as well.
In summary, we have demonstrated that DEC1 is a negative
regulator on the expression of DEC2. These two proteins ex-
hibit inversed expression patterns among paired samples from
the colon, kidney, and lung. An inducible expression system
demonstrates that increased expression of DEC1 proportion-
ally decreases the expression of DEC2. The DEC1-mediated
repression is primarily achieved by binding to the E-box in the
proximal promoter of DEC2. Site-directed mutagenesis studies
show that arginine 58 in the DNA binding domain is critical for
DEC1 to interact with this E-box. Given the fact that DEC/
STRA/SHARP proteins are emerging as very important regu-
lators in a vast array of cellular events including cell differen-
tiation, maturation of lymphocytes, oncogenesis, molecular
clock, and xenobiotic response, our findings described in this
study provide an important mechanism by which these pro-
teins regulate the cellular function by not only modulating the
expression of their target genes but also the expression of the
members within the same class.
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